Home Biosimilar Antibodies Angiogenesis VEGFR antibody Olinvacimab (Anti-VEGFR2 / KDR / CD309) For research use only.
Not for use in humans.

Olinvacimab (Anti-VEGFR2 / KDR / CD309)

Synonyms: TTAC-0001

Olinvacimab (Anti-VEGFR2 / KDR / CD309) is a fully human monoclonal antibody targeting VEGFR2. It has antiangiogenic activity and can be used for the research of recurrent glioblastoma and breast cancer. MW :146.88 KD

Olinvacimab (Anti-VEGFR2 / KDR / CD309)

Purity & Quality Control

≥99

Choose Selective VEGFR Inhibitors

Biological Activity

Description Olinvacimab (Anti-VEGFR2 / KDR / CD309) is a fully human monoclonal antibody targeting VEGFR2. It has antiangiogenic activity and can be used for the research of recurrent glioblastoma and breast cancer. MW :146.88 KD

Product Details

CAS No. 2095504-49-5
Molecular Weight 146.88
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Olinvacimab (Anti-VEGFR2 / KDR / CD309) | Olinvacimab (Anti-VEGFR2 / KDR / CD309) supplier | purchase Olinvacimab (Anti-VEGFR2 / KDR / CD309) | Olinvacimab (Anti-VEGFR2 / KDR / CD309) cost | Olinvacimab (Anti-VEGFR2 / KDR / CD309) manufacturer | order Olinvacimab (Anti-VEGFR2 / KDR / CD309) | Olinvacimab (Anti-VEGFR2 / KDR / CD309) distributor